In pathology, the protein Ki-67 is used to analyse conspicuous tissue changes. Researchers have discovered how this helpful protein is formed.
Compelling evidence suggests that many MS cases could be prevented by stopping EBV infection.
In 17% of patients with immune-mediated inflammatory diseases (IMID) on immunomodulating treatment, no seroconversion occurred after their first dose of SARS-CoV-2 vaccination.
The systemic immune-inflammation (SII) index emerged as a novel biomarker associated with a worse prognosis in different diseases.
Non-biologic systemic treatment more than doubled the risk for hospitalisation and death compared with tumour necrosis factor (TNF) inhibition.
Inhibition of heat shock protein 90 (HSP90) may be an interesting novel treatment mode for psoriasis. In a proof-of-concept trial, therapy with RGRN-305 showed marked efficacy with an acceptable safety profile.
Gene profiles for active psoriatic arthritis patients compared with healthy controls showed that genes related to neutrophils, monocytes, eosinophils, and macrophages are upregulated.
In a comparison of 5 commonly used systemic treatments for psoriasis, guselkumab demonstrated the highest drug survival and adalimumab the lowest at 1 and 2 years.
Psoriasis patients' microbiota are less diverse and have a decreased functional richness compared to healthy controls. Differences occured also in similar lifestyles of psoriasis patients and partners.
Most healthcare professionals perform dose reductions in psoriasis treatments. A main concern for professionals who do not taper biologics is the formation of anti-drug antibodies.
A real-world analysis from the BADBIR registry showed that drug survival of ustekinumab, but not from other biologics due to effectiveness, is associated with the psoriasis risk allele HLA-C*06:02.
A large registry study showed that psoriasis is linked with a higher cancer risk overall and in specific sites, particularly in severe disease. Psoriasis was associated with several cancers beyond those currently regarded as connected.
In a post-hoc investigation of diabetic participants in phase 3 trials, ixekizumab led to high proportions of Psoriasis Area and Severity Index amelioration.
During the COVID-19 pandemic lockdowns, results of the Dermatology Life Quality Index may have been altered by an increased number of “not-relevant” responses. DLQI-scores could be underestimated.
Gene expression patterns differed between lesional and non-lesional skin of patients with generalised pustular psoriasis with an upregulation.
Fitusiran prophylactic therapy reduced the ABR in severe haemophilia A or B patients without inhibitors. Quality of life increase was associated with fitusiran therapy.
The 5-azacitidine, venetoclax, and magrolimab combo had good response rates in newly diagnosed older, unfit, or TP53-mutated AML patients.
rFVIIIFc therapy realised immune tolerance in approximately 2 out of 3 patients with severe haemophilia A and high-titre inhibitors who underwent first ITI therapy.
Results from the POLARIX trial suggest that Pola-R-CHP may be the preferred first-line therapy for patients with diffuse large B-cell lymphoma.
Therapy de-escalation in patients with ALL and a low-risk MRD profile was safe, 10-year follow-up results of the UKALL 2003 trial show.